Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
504.50    -0.50 (-0.10%)
Bid:
504.50
Ask:
505.00
Spread: 0.50 (0.099%)
Market Cap: £2.23b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Trading Statement

26 Feb 2026 07:00

RNS Number : 4242U
Tate & Lyle PLC
26 February 2026
 

26 February 2026 - Tate & Lyle PLC

 

Q3 trading in line with expectations; outlook for the full-year unchanged;

focused on actions to drive top-line growth

 

Tate & Lyle issues the following trading statement for the nine months ended 31 December 2025.

Nick Hampton, Chief Executive said:

"Tate & Lyle's third quarter operating performance was in line with our expectations and consistent with the first half. 

In November, at our interim results, we outlined a series of actions to drive top-line growth and improve performance. We made good progress on these actions during the quarter. We continued to make targeted investments in capabilities and technology to strengthen our customer offering, and saw further encouraging momentum in customer engagement in our combined portfolio. The value of cross-selling opportunities in the new business pipeline increased significantly in the third quarter.

Delivering the benefits of the CP Kelco combination continues to progress well with run-rate cost synergies and revenue synergies tracking in line with our expectations. Our 5-year US$200m productivity programme remains on-track with further savings delivered during the quarter.

The renewal of customer framework agreements for the 2026 calendar year is well-advanced. With our number one priority returning the business to top-line growth, we have selectively chosen to invest to drive volume* and revenue growth. This is the right thing to do for the business, giving us a stronger platform for future growth and we are pleased with the engagement we are seeing from customers to our expanded offering.

In the near term, I am confident that the actions we are taking will improve the top-line performance of the business. Looking further ahead, our leading positions in sweetening, mouthfeel and fortification put us in a strong position to benefit from consumer demand for healthier, more nutritious food and drink. The breadth of our portfolio coupled with the targeted investments we are making to accelerate customer wins in key growth areas position us well to drive profitable revenue growth over time."

Trading

For the three months to 31 December 2025, Group revenue was 15% higher on a reported basis and in constant currency, reflecting the combination with CP Kelco on 15 November 2024. On a pro forma basis and in constant currency, revenue was 2% lower reflecting continued muted market demand. Performance in all regions was broadly in line with the first half.

For the nine months to 31 December 2025, on a pro forma basis revenue in the Americas was 2% lower than the prior period, with modestly higher pricing more than offset by lower volume*. In Europe, Middle East and Africa lower pricing resulted in 5% lower revenue, while in Asia Pacific revenue was up 1%, driven by higher volume*. 

Financial results

 

9 months to31 December 2025

 

Revenue

£m

Revenue change

reported1

%

Revenue Change

pro forma2

%

Americas

749

18%

(2)%

Europe, Middle East and Africa

475

27%

(5)%

Asia Pacific

282

79%

1%

Group

1 506

29%

(3)%

1 Comparative information is on a statutory basis, including CP Kelco from acquisition on 15 November 2024. Change is in constant currency.

2 Comparative information is pro forma basis, including the impact of CP Kelco for the entire period. CP Kelco acquisition completed 15 November 2024. Change is in constant currency.

Outlook

Our outlook for the 2026 financial year is unchanged from our interim results statement on 6 November 2025. For the year ending 31 March 2026, in constant currency and compared to pro forma comparatives, we continue to expect revenue and EBITDA to decline by low-single digit percent compared to the prior year.

Volume is the change in revenue in the period attributable to both the change in volume and the change in composition or mix of revenue.

END

 

Conference call

The third quarter conference call will be held today at 08.00am GMT hosted by Nick Hampton, Chief Executive and Sarah Kuijlaars, Chief Financial Officer. Please note that participants are required to pre-register for the call using this link. Following registration, participants will be sent an email containing dial in numbers and their unique pin codes. Participants are requested to dial-in at least 10 minutes before the start of the call. Dial in details are as follows:

 

UK dial in number: +44 (0)33 0551 0202

UK toll free number: 0808 109 0701

US dial in number: +1 786 496 5601

US toll free number: +1 866 571 0905

Conference ID: 6840649#

User ID: Provided upon registration (register here)

 

14 day conference call replay:

UK replay number: +44 (0)20 8196 1480

UK toll free replay number: 0800 640 6344

US toll free replay number: +1 866 583 1035

Access code: 6840649#

 

For more information contact Tate & Lyle PLC:

Kate Postans, VP, Investor Relations

Mobile: +44 (0)7388 702 934

 

Nick Hasell (FTI Consulting), Media Relations

Mobile: +44 (0)7825 523 383

 

About Tate & Lyle:

Supported by our 165-year history of ingredient innovation, we partner with customers to provide consumers with healthier and tastier choices when they eat and drink. We are proud that millions of people around the world consume products containing our ingredients and solutions every day. Through our leading expertise in sweetening, mouthfeel and fortication, we develop ingredients and solutions which reduce sugar, calories and fat, add bre and protein, and provide texture and stability to food and drink in categories including beverages, dairy, bakery, snacks, soups, sauces, and dressings

 

Tate & Lyle recently acquired CP Kelco, a leading provider of pectin, speciality gums and other nature-based ingredients to create a leader in mouthfeel, significantly enhancing our solutions capabilities. Following this combination, we now have more than 5,000 employees working in around 75 locations in 38 countries, serving customers in more than 120 countries. Science, Solutions, Society is our brand promise and how we will achieve our purpose of Transforming Lives through the Science of Food. By living our purpose, we believe we can successfully grow our business and have a positive impact on society. We live our purpose in three ways, by supporting healthy living, building thriving communities and caring for our planet.

 

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. For the year ended 31 March 2025, and on a pro forma basis which assumes for illustrative purposes that the combination with CP Kelco took place on 1 April 2024, revenue for the enlarged Tate & Lyle Group would have been £2.12 billion. For more information, please visit www.tateandlyle.com or follow Tate & Lyle on LinkedIn, X (Twitter), Facebook or YouTube. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTAKPBKOBKDDBB
Date   Source Headline
2nd Jun 20203:56 pmRNSDirector/PDMR Shareholding
21st May 20207:00 amRNSFinal Results
4th May 20207:00 amRNSTrading Update
1st May 20203:27 pmRNSTotal Voting Rights
3rd Apr 202011:00 amRNSDirector Declaration
1st Apr 202012:26 pmRNSTotal Voting Rights
6th Feb 20207:00 amRNSTrading Statement
30th Jan 202011:45 amRNSDirector/PDMR Shareholding
7th Jan 20202:00 pmRNSDirector/PDMR Shareholding
2nd Jan 202012:41 pmRNSBlock listing Interim Review
19th Dec 20192:00 pmRNSDirector/PDMR Shareholding
7th Nov 20197:00 amRNSHalf-year Report
3rd Oct 20193:06 pmRNSHolding(s) in Company
1st Oct 201910:14 amRNSTotal Voting Rights
19th Sep 20197:00 amRNSFULL PENSION SCHEME BUY-IN WITH LEGAL & GENERAL
6th Sep 201910:15 amRNSDirector/PDMR Shareholding
30th Aug 201912:00 pmRNSDirector Declaration
21st Aug 201910:00 amRNSDirector/PDMR Shareholding
5th Aug 20193:00 pmRNSIssue of Debt
1st Aug 20192:00 pmRNSTotal Voting Rights
25th Jul 201912:58 pmRNSResult of AGM
18th Jul 20193:00 pmRNSDirector/PDMR Shareholding
17th Jul 20197:02 amRNSChange to Executive Committee
1st Jul 201912:40 pmRNSBlock listing Interim Review
1st Jul 201912:38 pmRNSTotal Voting Rights
1st Jul 201912:00 pmRNSDirector/PDMR Shareholding
10th Jun 201911:30 amRNSAnnual Financial Report
5th Jun 20199:52 amRNSHolding(s) in Company
5th Jun 20199:34 amRNSDirector/PDMR Shareholding
3rd Jun 201910:42 amRNSTotal Voting Rights
29th May 20194:00 pmRNSDirector/PDMR Shareholding
28th May 20194:12 pmRNSDirector/PDMR Shareholding
23rd May 20197:00 amRNSFinal Results
9th May 201911:00 amRNSDirectorate Change
1st May 201910:00 amRNSTotal Voting Rights
1st Apr 20194:17 pmBUSTotal Voting Rights
1st Apr 20193:45 pmBUSHolding(s) in Company
1st Mar 201911:21 amBUSTotal Voting Rights
27th Feb 20191:00 pmBUSHolding(s) in Company
7th Feb 20197:00 amBUSTrading Statement
1st Feb 201911:40 amBUSTotal Voting Rights
3rd Jan 20192:00 pmBUSDirector/PDMR Shareholding
2nd Jan 20193:53 pmBUSBlock listing Interim Review
6th Dec 201811:32 amBUSDirector/PDMR Shareholding
5th Dec 20182:22 pmBUSDirector/PDMR Shareholding
3rd Dec 20183:34 pmBUSTotal Voting Rights
19th Nov 20187:00 amBUSDirectorate change
8th Nov 20187:00 amBUSHalf-year Report
1st Nov 201812:20 pmBUSTotal Voting Rights
5th Oct 20182:05 pmBUSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.